Lewis Vidler is a senior research scientist at Lilly. He achieved a first class chemistry degree at the University of Oxford in 2009, spending the final year in the organic chemistry lab of Professor Michael Willis. He then went on to complete a PhD in computational medicinal chemistry at the Institute of Cancer research in London, publishing a number of highly cited papers on bromodomains, and was given the Chairman’s award for best PhD student. Lewis then joined Lilly in 2013, initially as a contractor, but was made an FTE less than a year later. His interests span all aspects of drug discovery, especially medicinal chemistry and compound design. His role at Lilly is primarily computational project support, but is doing increasing amounts of work to automate various aspects of the drug discovery process.